Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Filimonova I, Schmidt D, Mansoorian S, Weissmann T, Siavooshhaghighi H, Cavallaro A, Kuwert T, Bert C, Frey B, Distel LV, Lettmaier S, Fietkau R, Putz F. The Distribution of Pelvic Nodal Metastases in Prostate Cancer Reveals Potential to Advance and Personalize Pelvic Radiotherapy. Front Oncol 2021;10:590722. [PMID: 33489887 PMCID: PMC7820617 DOI: 10.3389/fonc.2020.590722] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2020] [Accepted: 11/16/2020] [Indexed: 12/01/2022] Open

For:	Filimonova I, Schmidt D, Mansoorian S, Weissmann T, Siavooshhaghighi H, Cavallaro A, Kuwert T, Bert C, Frey B, Distel LV, Lettmaier S, Fietkau R, Putz F. The Distribution of Pelvic Nodal Metastases in Prostate Cancer Reveals Potential to Advance and Personalize Pelvic Radiotherapy. Front Oncol 2021;10:590722. [PMID: 33489887 PMCID: PMC7820617 DOI: 10.3389/fonc.2020.590722] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2020] [Accepted: 11/16/2020] [Indexed: 12/01/2022] Open

Number

Cited by Other Article(s)

Weissmann T, Mansoorian S, May MS, Lettmaier S, Höfler D, Deloch L, Speer S, Balk M, Frey B, Gaipl US, Bert C, Distel LV, Walter F, Belka C, Semrau S, Iro H, Fietkau R, Huang Y, Putz F. Deep Learning and Registration-Based Mapping for Analyzing the Distribution of Nodal Metastases in Head and Neck Cancer Cohorts: Informing Optimal Radiotherapy Target Volume Design. Cancers (Basel) 2023;15:4620. [PMID: 37760588 PMCID: PMC10526893 DOI: 10.3390/cancers15184620] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2023] [Revised: 09/15/2023] [Accepted: 09/15/2023] [Indexed: 09/29/2023] Open

Affiliation(s)

Thomas Weissmann Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany; (T.W.); (S.L.); (D.H.); (L.D.); (S.S.); (B.F.); (U.S.G.); (C.B.); (L.V.D.); (S.S.); (R.F.) Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany; (M.S.M.); (M.B.); (H.I.) Bavarian Cancer Research Center (BZKF), 81377 Munich, Germany; (S.M.); (F.W.); (C.B.)
Sina Mansoorian Bavarian Cancer Research Center (BZKF), 81377 Munich, Germany; (S.M.); (F.W.); (C.B.) Department of Radiation Oncology, University Hospital, Ludwig Maximilian University of Munich, 81377 Munich, Germany
Matthias Stefan May Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany; (M.S.M.); (M.B.); (H.I.) Department of Radiology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany
Sebastian Lettmaier Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany; (T.W.); (S.L.); (D.H.); (L.D.); (S.S.); (B.F.); (U.S.G.); (C.B.); (L.V.D.); (S.S.); (R.F.) Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany; (M.S.M.); (M.B.); (H.I.)
Daniel Höfler Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany; (T.W.); (S.L.); (D.H.); (L.D.); (S.S.); (B.F.); (U.S.G.); (C.B.); (L.V.D.); (S.S.); (R.F.) Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany; (M.S.M.); (M.B.); (H.I.)
Lisa Deloch Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany; (T.W.); (S.L.); (D.H.); (L.D.); (S.S.); (B.F.); (U.S.G.); (C.B.); (L.V.D.); (S.S.); (R.F.) Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany; (M.S.M.); (M.B.); (H.I.) Translational Radiobiology, Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany
Stefan Speer Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany; (T.W.); (S.L.); (D.H.); (L.D.); (S.S.); (B.F.); (U.S.G.); (C.B.); (L.V.D.); (S.S.); (R.F.) Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany; (M.S.M.); (M.B.); (H.I.)
Matthias Balk Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany; (M.S.M.); (M.B.); (H.I.) Department of Otolaryngology, Head and Neck Surgery, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany
Benjamin Frey Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany; (T.W.); (S.L.); (D.H.); (L.D.); (S.S.); (B.F.); (U.S.G.); (C.B.); (L.V.D.); (S.S.); (R.F.) Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany; (M.S.M.); (M.B.); (H.I.) Translational Radiobiology, Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany
Udo S. Gaipl Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany; (T.W.); (S.L.); (D.H.); (L.D.); (S.S.); (B.F.); (U.S.G.); (C.B.); (L.V.D.); (S.S.); (R.F.) Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany; (M.S.M.); (M.B.); (H.I.) Translational Radiobiology, Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany
Christoph Bert Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany; (T.W.); (S.L.); (D.H.); (L.D.); (S.S.); (B.F.); (U.S.G.); (C.B.); (L.V.D.); (S.S.); (R.F.) Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany; (M.S.M.); (M.B.); (H.I.)
Luitpold Valentin Distel Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany; (T.W.); (S.L.); (D.H.); (L.D.); (S.S.); (B.F.); (U.S.G.); (C.B.); (L.V.D.); (S.S.); (R.F.) Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany; (M.S.M.); (M.B.); (H.I.)
Franziska Walter Bavarian Cancer Research Center (BZKF), 81377 Munich, Germany; (S.M.); (F.W.); (C.B.) Department of Radiation Oncology, University Hospital, Ludwig Maximilian University of Munich, 81377 Munich, Germany
Claus Belka Bavarian Cancer Research Center (BZKF), 81377 Munich, Germany; (S.M.); (F.W.); (C.B.) Department of Radiation Oncology, University Hospital, Ludwig Maximilian University of Munich, 81377 Munich, Germany
Sabine Semrau Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany; (T.W.); (S.L.); (D.H.); (L.D.); (S.S.); (B.F.); (U.S.G.); (C.B.); (L.V.D.); (S.S.); (R.F.) Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany; (M.S.M.); (M.B.); (H.I.)
Heinrich Iro Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany; (M.S.M.); (M.B.); (H.I.) Department of Otolaryngology, Head and Neck Surgery, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany
Rainer Fietkau Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany; (T.W.); (S.L.); (D.H.); (L.D.); (S.S.); (B.F.); (U.S.G.); (C.B.); (L.V.D.); (S.S.); (R.F.) Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany; (M.S.M.); (M.B.); (H.I.) Bavarian Cancer Research Center (BZKF), 81377 Munich, Germany; (S.M.); (F.W.); (C.B.)
Yixing Huang Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany; (T.W.); (S.L.); (D.H.); (L.D.); (S.S.); (B.F.); (U.S.G.); (C.B.); (L.V.D.); (S.S.); (R.F.) Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany; (M.S.M.); (M.B.); (H.I.)
Florian Putz Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany; (T.W.); (S.L.); (D.H.); (L.D.); (S.S.); (B.F.); (U.S.G.); (C.B.); (L.V.D.); (S.S.); (R.F.) Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany; (M.S.M.); (M.B.); (H.I.) Bavarian Cancer Research Center (BZKF), 81377 Munich, Germany; (S.M.); (F.W.); (C.B.)

Collapse

Vogel MME, Düsberg M, Stöhrer L, Dewes S, Sage EK, Borm KJ, Gschwend JE, Eiber M, Combs SE, Schiller K. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography-based Lymph Node Atlas for Salvage Radiotherapy in Patients with Recurrent Prostate Cancer: A Validation of the New NRG Oncology 2020 guideline. Eur Urol Oncol 2022;5:668-676. [PMID: 36280446 DOI: 10.1016/j.euo.2022.09.006] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2022] [Revised: 09/07/2022] [Accepted: 09/30/2022] [Indexed: 01/26/2023]

Abstract

BACKGROUND

Approximately 20-40% of patients with prostate cancer (PC) who undergo radical prostatectomy (RP) experience relapse, with the majority of these cases developing pelvic lymph node (LN) metastases. Taking new data from the prostate-specific membrane antigen (PSMA) positron emission tomography (PET) era into account, the Radiation Therapy Oncology Group (RTOG) 2009 contouring guideline for the pelvic LNs from 2009 was updated by the NRG Oncology group in 2020 (NRG 2020).

OBJECTIVE

To evaluate and validate the updated NRG 2020 guideline with our established LN atlas.

DESIGN, SETTING, AND PARTICIPANTS

We screened 1653 PSMA PET/computed tomography (CT) data sets for patients with biochemical relapse who underwent a PET scan between November 2012 and November 2017. After screening, we developed an LN atlas using data from 233 patients.

OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS

We evaluated LN overlap (OL) with the RTOG 2009 and NRG 2020 contouring guidelines. OL was defined as within (>90%), partly within (10-90%), or outside (<10%).

RESULTS AND LIMITATIONS

In comparison to the RTOG 2009 guideline, 403 (52%), 134 (17%), and 241 (31%) of the LNs were not, were partly, or were fully covered within the overall group, respectively. By contrast, using the NRG 2020 guideline, 302 (39%), 190 (24%), and 286 (37%) of the LNs were not, were partly, or were fully covered, respectively (p < 0.001). Limitations include the retrospective design with missing data and no histopathological confirmation of the PET results.

CONCLUSIONS

The updated NRG 2020 contouring guideline improves coverage of the pelvic LNs in patients undergoing salvage radiation therapy. However, PET/CT should be considered whenever possible to ensure coverage of untypical LN spread.

PATIENT SUMMARY

We compared the 2009 and 2020 guidelines on the radiation area for the pelvis for patients with recurrent prostate cancer that has spread to lymph nodes. The newer guideline provides better coverage of pelvic lymph nodes than the older one and is useful in planning radiation therapy. However, a scan of the pelvis using the newest technique should be considered for individual patients to ensure coverage of untypical lymph nodes.

Collapse

Guler OC, Onal C. In Regard to Harmon et al. Int J Radiat Oncol Biol Phys 2022;112:572-573. [PMID: 34998536 DOI: 10.1016/j.ijrobp.2021.09.037] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2021] [Accepted: 09/21/2021] [Indexed: 10/19/2022]

In Reply to Guler and Onal. Int J Radiat Oncol Biol Phys 2022;112:573-574. [PMID: 34998537 DOI: 10.1016/j.ijrobp.2021.09.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2021] [Accepted: 09/21/2021] [Indexed: 11/22/2022]